Q3 2025 · 13F-HR
REGENERON PHARMACEUTICALS, INC. (REGN)holdings as filed
Filed 2025-11-07 · accession 0001104659-25-108546
$700.4M
Reported value
4
Positions
2025-09-30
Period end
The Brief · REGENERON PHARMACEUTICALS, INC. (REGN) · Q3 2025
AI · grounded in 13F
REGENERON PHARMACEUTICALS, INC. (REGN) established a new position in Alnylam Pharmaceuticals, Inc. ALNY valued at $634.89M. The fund also initiated a position in Intellia Therapeutics, Inc. NTLA worth $63.95M. Additional new holdings include Adverum Biotechnologies, Inc. AVU0 and Adicet Bio, Inc. TORCEUR.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 02043Q107 | ALNY | Alnylam Pharmaceuticals, Inc. | $634.9M | 90.6% | 1,392,303 | Common | SOLE |
| 45826J105 | NTLA | Intellia Therapeutics, Inc. | $64.0M | 9.13% | 3,702,995 | Common | SOLE |
| 00773U207 | AVU0 | Adverum Biotechnologies, Inc. | $819,518 | 0.12% | 180,909 | Common | SOLE |
| 007002108 | TORCEUR | Adicet Bio, Inc. | $784,422 | 0.11% | 968,183 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.